Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

In a heartening milestone for pediatric care and collective compassion, baby Aasmika Das from West Bengal has successfully ...

Aasmika Das, a baby from West Bengal, underwent a life-changing Zolgensma gene therapy for Spinal Muscular Atrophy Type 1, thanks to INR 8.41 crore raised by 5.29 lakh donors through Impact Guru. Her ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...

The family has received ₹60 lakh so far and hopes that it will be able to collect ₹14.5 crore required for treatment ...

BiogenBIIB said Wednesday its experimental treatment helped children with a devastating muscle-wasting disease even after they received an approved gene therapy from NovartisNVS.The company already ...

Zolgensma’s price quickly became the standard for gene therapies. Nine of them cost more than $2 million. A tenth, approved in November, is predicted to run about $3.8 million, ...

Zolgensma is a prescription drug to treat spinal muscular atrophy in certain children. Learn about the drug’s dosage, form, administration, and more.

Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an ...

Zolgensma is a prescription drug that’s used to treat spinal muscular atrophy (SMA) in young children. Zolgensma’s cost may depend on factors such as your child’s treatment plan and whether ...

Zolgensma works by replacing the missing or nonfunctioning gene causing S.M.A. with a working copy of the gene. It has been given to more than 2,500 children and approved for use in 46 countries.